Lenvatinib + Nivolumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Hepatocellular Carcinoma
Conditions
Advanced Hepatocellular Carcinoma
Trial Timeline
Jun 12, 2019 → May 2, 2023
NCT ID
NCT03841201About Lenvatinib + Nivolumab
Lenvatinib + Nivolumab is a phase 2 stage product being developed by Eisai for Advanced Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03841201. Target conditions include Advanced Hepatocellular Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Hepatocellular Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03841201 | Phase 2 | Completed |
| NCT03418922 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Hepatocellular Carcinoma